March 29, 2011, 9:16 AM EDT / Source: GlobeNewswire PALO ALTO, Calif., March 29, 2011 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today the launch of three new cell culture supplements ...
PALO ALTO, Calif., Nov. 15, 2010 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that is has filed an application with Swissmedic, the Swiss regulatory agency for therapeutic ...
Biotech firm StemCells plans to dissolve its operations following the failure of a clinical trial that was testing a treatment for spinal cord injury. The Newark, Calif.-based firm said it would ...
Palo Alto-based biotech company StemCells announced Friday that it has entered into a definitive agreement with an institutional investor to provide the company with up to $30 million in equity ...
PALO ALTO, Calif., Aug. 31, 2010 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that its technology was recently used by independent researchers to achieve the first genetically ...
When a company is in real trouble, using simple math to make its stock look more attractive, or burying bad news at the bottom of a press release, doesn’t usually help for long. Biotech StemCells Inc.
Award to Fund IND-Enabling Activities for the Company's HuCNS-SC(R) Neural Stem Cells in Alzheimer's Disease NEWARK, Calif., Sep 6, 2012 (GlobeNewswire via COMTEX) -- StemCells, Inc. STEM -0.24% today ...
StemCells has terminated the make-or-break phase 2 clinical trial of its neural stem cell therapy for spinal cord injuries and plans to close its doors. The company, located in Newark, California, is ...
The state’s political watchdog investigated but didn’t pursue Alan Trounson after he went to StemCells Inc. Eric Risberg Associated Press file The former president of the $3 billion California stem ...
Federal funding doesn't matter for most stem cell companies. Investors in stem cells companies seem to have finally realized that federal funding of stem cell research isn't all that important for ...
Award to Fund IND-Enabling Activities for the Company's HuCNS-SC(R) Neural Stem Cells in Alzheimer's Disease NEWARK, Calif., Sept. 6, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today ...
StemCells said today it will shrink its workforce by about 25% by January 31, 2016, as part of a restructuring that will include selling off assets and refocusing clinical efforts away from retinal ...
NEWARK, Calif., Sept. 18, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced the publication of preclinical data confirming that the Company's proprietary HuCNS-SC cells (purified ...
StemCells Inc. and three other research projects won a total of $63 million in funding Wednesday night from California's stem cell research funding agency. StemCells Inc. and three other research ...
Dec. 6, 2010, 9:15 AM EST / Source: GlobeNewswire PALO ALTO, Calif., Dec. 6, 2010 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today the launch of STEM101™, STEM121™ and STEM123™, three ...
PALO ALTO, Calif. and ORANGE, Calif., June 3, 2010 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) (the "Company") and the Children's Hospital of Orange County ("CHOC Children's") announced today ...
PALO ALTO, Calif., June 15, 2011 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that it will present evidence of engraftment, migration and the long-term survival of its proprietary ...
June 10, 2013 09:00 | Source: StemCells, Inc. NEWARK, Calif., June 10, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced key hires to strengthen its product development ...
PALO ALTO, Calif., Nov. 15, 2010 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM - News) announced today that is has filed an application with Swissmedic, the Swiss regulatory agency for therapeutic ...
StemCells, Inc. is engaged in the research, development, and commercialization of stem cell therapeutics and tools for use in stem cell-based research and drug discovery.